Nektar Therapeutics (ITH0) Stock Overview
A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ITH0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.49 |
| 52 Week High | US$90.68 |
| 52 Week Low | US$7.26 |
| Beta | 1.15 |
| 1 Month Change | -29.66% |
| 3 Month Change | -20.51% |
| 1 Year Change | 457.36% |
| 3 Year Change | 509.71% |
| 5 Year Change | -77.72% |
| Change since IPO | -70.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ITH0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 4.9% | -2.9% |
| 1Y | 457.4% | 23.4% | -0.8% |
Return vs Industry: ITH0 exceeded the German Pharmaceuticals industry which returned 24% over the past year.
Return vs Market: ITH0 exceeded the German Market which returned -0.5% over the past year.
Price Volatility
| ITH0 volatility | |
|---|---|
| ITH0 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: ITH0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ITH0's weekly volatility has decreased from 23% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 63 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
Nektar Therapeutics Fundamentals Summary
| ITH0 fundamental statistics | |
|---|---|
| Market cap | €1.66b |
| Earnings (TTM) | -€136.96m |
| Revenue (TTM) | €48.19m |
Is ITH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITH0 income statement (TTM) | |
|---|---|
| Revenue | US$55.63m |
| Cost of Revenue | US$0 |
| Gross Profit | US$55.63m |
| Other Expenses | US$213.73m |
| Earnings | -US$158.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -284.18% |
| Debt/Equity Ratio | 10.5% |
How did ITH0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 10:12 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nektar Therapeutics is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |
| George Farmer | BMO Capital Markets Equity Research |